This guidance replaces previous conditional recommendations for the use of these drugs and is based on emerging evidence that they’re not likely to work against omicron.
Articles on covid treatment
Displaying all articles
After taking Paxlovid for COVID and appearing to recover, some people – including US President Joe Biden – continue to test positive. What’s going on?
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
If you do get COVID and you’re eligible for antiviral treatment, you’ll want to get them quickly. That’s why being prepared is a good idea.
After testing positive for COVID, your medicine prescription will depend on the severity of your symptoms and any other health conditions you have.
Here’s who is eligible, the benefits and side effects to consider.
Most people with COVID will recover at home without any treatment. But some people who are at risk of severe disease could benefit from new medicines to reduce the chance of the disease progressing.
These new antivirals are another way of managing COVID-19. But they’re not a panacea, and could even makes things worse.
The need of the moment is for low- and middle-income countries to improve their own manufacturing capabilities.
Who gets scarce life-saving resources when hospitals are overwhelmed? And how are these decisions made? State and territory governments are yet to answer these difficult questions.
If you feel like you’re having a medical emergency then you should still go to hospital. Expect longer waits and extra precautions.
Top contributors
-
Director, Australian Living Evidence Collaboration; Professor (Research), School of Population Health and Preventive Medicine, Monash University
-
Monash University
-
Senior Lecturer in Pharmacy and Pharmacology, Head of Breast Cancer Targeting and Drug Delivery Laboratory, University of Sydney
-
Professor of Law, Australian Centre for Health Law Research, Queensland University of Technology
-
Professor of Cancer Virology, University of Leeds
-
Post doctoral researcher and medical epidemiologist, The Peter Doherty Institute for Infection and Immunity
-
Senior Research Fellow, Discipline of General Practice, and Specialist General Practitioner, Adelaide University
-
Senior Lecturer, Australian Centre for Health Law Research, Faculty of Business and Law, Queensland University of Technology
-
Professor in Law, University of Southern Queensland
-
Associate Professor in Viral Immunology, University of Birmingham
-
Senior lecturer, Australian National University
-
Conjoint Professor, School of Medicine and Public Health, University of Newcastle
-
Professor of General Practice, Bond University
-
Pharmacist and PhD Candidate, University of Sydney
-
A/Professor, paediatrician, infectious diseases physician and clinical pharmacologist, Murdoch Children's Research Institute